The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
about
Appraisal of immunoglobulin free light chain as a marker of responseClinical and biological significance of RAS mutations in multiple myeloma.Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survivalThe treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative OncPhase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalImpact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder.Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myelomaThalidomide in the treatment of multiple myeloma.A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myelomaUncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approachGenetic aberrations and survival in plasma cell leukemiaEstimating predictors for long- or short-term survivors.Myeloma (multiple).
P2860
Q24624398-3350826B-0638-4C08-B361-FF03D4030BFEQ27851434-E734445C-EB13-4F4F-8A7D-E21045B352ECQ30655745-F85C6BF9-309D-4FD9-9A3B-975DDA0B7B1CQ33367792-2D9B9274-B4BC-4948-B140-CD6C3ADB6254Q33789545-5DC92925-3C45-4157-BB61-60454FF41805Q33805334-D617829E-8A1F-4EE5-90F1-EA57B02A65DAQ34011489-FB7A35C6-D91E-4BBD-B0FA-795253C5FA8FQ34115051-4278DF10-2E9F-42E9-90FB-B5CDE315B61BQ34275888-3511901D-0492-4345-BBE8-5ECE2E96EC71Q34312459-0716D2EF-D21A-4B3F-8240-F0FEC4462669Q34734291-C92DD7FF-0292-41BC-965C-68DD628BF107Q35847898-801CC1B3-6DCD-4621-933D-6A9834DD3529Q36572310-10915802-FC69-4DBD-9219-BD9CC4334D66Q36779423-80217A45-487C-46DE-B68A-1697B8AAE738Q37486780-879F582B-6F4A-4FC3-923B-C3A4437D553AQ40530949-C3FC8FAD-8997-42FC-BAD3-AC733ACB8D33Q46721437-FFEBBE51-8E93-45BA-A3F3-C1ABB6848F6B
P2860
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
The addition of interferon or ...... Group Clinical Trial EST 9486.
@en
The addition of interferon or ...... Group Clinical Trial EST 9486.
@nl
type
label
The addition of interferon or ...... Group Clinical Trial EST 9486.
@en
The addition of interferon or ...... Group Clinical Trial EST 9486.
@nl
prefLabel
The addition of interferon or ...... Group Clinical Trial EST 9486.
@en
The addition of interferon or ...... Group Clinical Trial EST 9486.
@nl
P2093
P1433
P1476
The addition of interferon or ...... Group Clinical Trial EST 9486.
@en
P2093
Keimowitz RM
Lenhard RE Jr
Van Ness B
P304
P356
10.1002/(SICI)1097-0142(19990915)86:6<957::AID-CNCR10>3.3.CO;2-#
P407
P577
1999-09-01T00:00:00Z